Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management Strategies for OAB in Post-Surgical SVM Patients
NCT03280316Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Randomised, open-label trial of botulinum toxin type A and tolterodine in overactive bladder (OAB) (3 arms), sponsored by Xuanwu Hospital. Primary endpoint: Bladder function at 12 months. Status: unknown.
02
Drugs
botulinum toxin type Atolterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03280316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280316.